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Typhoid fever, caused by the human-restricted organism Salmonella enterica serovar 
Typhi (S. Typhi), constitutes a major global health problem. The development of improved 
attenuated vaccines is pressing, but delayed by the lack of appropriate preclinical mod-
els. Herein, we report that high levels of S. Typhi-responsive CD8+ T cells at baseline 
significantly correlate with an increased risk of disease in humans challenged with a high 
dose (~104 CFU) wild-type S. Typhi. Typhoid fever development was associated with 
higher multifunctional S. Typhi-responsive CD8+ T effector memory cells at baseline. 
Early decreases of these cells in circulation following challenge were observed in both 
S. Typhi-responsive integrin α4β7− and integrin α4β7+ CD8+ T effector memory (TEM) 
cells, suggesting their potential to home to both mucosal and extra-intestinal sites. 
Participants with higher baseline levels of S. Typhi-responsive CD8+ T memory cells had 
a higher risk of acquiring disease, but among those who acquired disease, those with a 
higher baseline responses took longer to develop disease. In contrast, protection against 
disease was associated with low or absent S. Typhi-responsive T cells at baseline and no 
changes in circulation following challenge. These data highlight the importance of pre-ex-
isting S. Typhi-responsive immunity in predicting clinical outcome following infection with 
wild-type S. Typhi and provide novel insights into the complex mechanisms involved in 
protective immunity to natural infection in a stringent human model with a high challenge 
dose. They also contribute important information on the immunological responses to be 
assessed in the appraisal and selection of new generation typhoid vaccines.
Keywords: typhoid fever, Salmonella Typhi, cell-mediated immunity, cD8+ T cells, multifunctional, cytotoxicity, 
cytokines
Abbreviations: CMI, cell-mediated immunity; TN, naïve T; TCM, T central memory; TEM, T effector memory; TEMRA, T effector 
memory CD45RA+.
2Fresnay et al. CD8+ T Cell Immunity in Typhoid Fever
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 208
inTrODUcTiOn
Typhoid fever remains a major public health priority worldwide, 
with an estimated 21.7 million cases and 200,000 deaths per year 
(1). Salmonella enterica serovar Typhi (S. Typhi) is a human-
restricted facultative intracellular Gram negative organism that 
causes typhoid fever (2). A better understanding of the immuno-
logical correlates of protection against S. Typhi is required for the 
development of improved attenuated typhoid vaccines. However, 
current knowledge is limited due to the difficulties associated with 
performing challenge studies in humans and the lack of an animal 
model that faithfully recapitulates human disease. Nevertheless, 
the S. Typhimurium “typhoid” mouse model has led to important 
insights into the role that various innate and adaptive effector 
mechanisms might play in protection from Salmonella infection, 
including production of interferon (IFN)-γ and tumor necrosis 
factor (TNF)-α by CD8+ T cells (3).
Human typhoid challenge studies were performed in the 
1960s at the University of Maryland to improve understanding 
of typhoid fever (4, 5), and constituted a first step toward licen-
sure of the oral attenuated Ty21a typhoid vaccine (6). However, 
due to the rudimentary immunological assays available at that 
time, this research did not document cellular-mediated immune 
responses (CMI) against S. Typhi and provided only very limited 
understanding of possible immunological correlates of protec-
tion. Significant information has been derived from studies that 
examined immune responses in typhoid patients after infection 
in the field and development of clinical typhoid disease or fol-
lowing vaccination with attenuated typhoid oral vaccines (7). 
However, these studies do not provide insights into the immuno-
logical status before wild-type infection and its possible effects 
on clinical outcome. The human challenge model was recently 
developed by the Oxford Vaccine Group (OVG, University of 
Oxford) where naïve participants ingested wild-type (wt) S. 
Typhi (Quailes strain) (8–10). The re-establishment of this 
challenge model allowed us, for the first time, to use advanced 
immunological tools to study the relationship between a sub-
ject’s pre-challenge immunologic status and subsequent clinical 
outcome following exposure to wt S. Typhi, as well as to initiate 
detailed studies of the immunological correlates of protection in 
typhoid fever (11).
A considerable body of literature in subjects immunized 
orally with Ty21a and attenuated typhoid vaccine candidates 
suggest that CMI responses, in particular CD8+ effector T cells, 
may play a crucial role in limiting the progression of typhoid 
fever by destroying host cells infected with S. Typhi (12, 13). 
CD8+ T cells may contribute to the control of infection through 
cytolytic activity and/or production of T helper 1/T cytotoxic 1, 
as well as Th17 cytokines (7, 11, 14–23). Multiphasic cytokine 
production by CD8+ T cells in participants immunized with 
live-attenuated typhoid vaccine Ty21a has been described 
in response to antigenic presentation by class Ia HLA and by 
non-classical HLA-E molecules, the latter molecule being less 
polymorphic and likely to present a more conserved set of bacte-
rial peptides (7, 21, 22). Furthermore, detailed characterization 
of the simultaneous production of cytokines (co-production) by 
individual CD8+ T cells identified persistent S. Typhi-specific 
multifunctional (MF) CD8+ T cells following oral immuniza-
tion with Ty21a (22). Finally, very recently, the closely monitored 
experimental human infection model with wt S. Typhi allowed 
us to provide the first evidence that CD8+ responses directed 
against S. Typhi correlate with clinical outcome in humans. 
This was observed in the group of participants challenged with 
a relatively low dose (~103  CFU) of wild-type S. Typhi (11). 
Higher MF S. Typhi-responsive CD8+ T cells at baseline were 
associated with protection against typhoid and delayed disease 
onset. Moreover, following challenge, development of typhoid 
fever was accompanied by decreases in circulating S. Typhi-
responsive CD8+ T effector memory (TEM) with gut homing 
potential, suggesting migration to the site(s) of infection. In 
contrast, protection against disease was associated with low or 
no changes in circulating S. Typhi-responsive TEM (11).
In the present study, we characterized CMI responses directed 
against S. Typhi before pathogen exposure in participants from 
the Oxford study challenged with a high dose of wt S. Typhi 
(~104  CFU). We evaluated the relationship between baseline 
levels of S. Typhi-responsive CD8+ T cells responses and clinical 
outcome. We also investigated the kinetic patterns of S. Typhi-
responsive CD8+ T cells following challenge, as well as their 
expression of the gut homing molecule integrin α4β7 in relation-
ship with typhoid diagnosis. Finally, we characterized in depth 
the MF properties of the responses against S. Typhi to identify 
the dominant MF patterns associated with clinical outcome by 
simultaneously evaluating the production of macrophage inflam-
matory protein (MIP)-1β, IFN-γ, TNF-α, interleukin (IL)-2, and 
IL-17A, as well as the expression of the cytotoxicity degranulation 
marker CD107a (24). The results described herein demonstrate 
that baseline responses directed against S. Typhi are related to 
clinical outcome following infection with a high dose (~104 CFU) 
of wt S. Typhi in a stringent human challenge model.
MaTerials anD MeThODs
Participants and challenge
Twenty healthy, male or female participants aged 18–60  years 
were recruited by the Oxford Vaccine Group, UK, to participate 
in this phase II clinical study. The demographic characteristics 
of the participants are described in Table S1 in Supplementary 
Material. Any participant who had previously received typhoid 
vaccination, resided for over 6 months in typhoid-endemic areas, 
or was previously diagnosed with probable or confirmed typhoid 
infection was excluded from this study. The extensive exclusion 
criteria also included evidence of gallbladder disease, allergy to 
antibiotics, food handling, contact with susceptible individuals, 
acute or exacerbation of chronic infection within the previous 
7 days or fever within the previous 3 days, and a history of having 
been treated with antibiotics or corticosteroids in the previous 
14 days (8).
Participants were challenged orally with a dose of 
1–5 × 104 CFU of wt S. Typhi (Quailes strain) administered after 
neutralization of gastric acid with NaHCO3 and monitored closely 
as previously described (8). Positive typhoid fever diagnosis (TD) 
was determined by blood culture-confirmed S. Typhi bacteremia 
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or development of a fever of ≥38°C for ≥12 h, and participants 
were treated as previously described (8). Written informed 
consent was obtained in accordance with the Declaration of 
Helsinki. All procedures were approved by National Research 
Ethic Service (NRES), Oxfordshire Research Ethics Comittee 
A (10/H0604/53) and conducted in accordance with the prin-
ciples of the International Conference of Harmonisation Good 
Clinical Practice guidelines. All participants enrolled in this study 
[13 participants diagnosed with typhoid (TD) and 7 participants 
who were not diagnosed with typhoid (NoTD)] were evaluated 
for their T cell effector functions.
specimen collection and isolation of 
Peripheral Blood Mononuclear cells 
(PBMc)
Routine blood hematology was performed before challenge, 
on alternate days after challenge, and at typhoid diagnosis. 
PBMC were isolated by Lymphoprep gradient centrifugation 
(STEMCELL Technologies, Vancouver, BC, Canada) and stored 
in liquid N2. Upon thawing, viability and recovery were measured 
as previously described (11), and cells were rested overnight in 
complete RPMI [cRPMI: RPMI 1640 media (Gibco, Carlsbad, 
CA, USA) supplemented with 100  U/ml penicillin (Sigma), 
100 μg/ml streptomycin (Sigma), 50 μg/ml gentamicin (Gibco), 
2 mM l-glutamine (Gibco), 10 mM HEPES buffer (Gibco), and 
10% heat-inactivated fetal bovine serum (Gemini Bioproducts, 
West Sacramento, CA, USA)] to serve as effector cells in CMI 
assays.
stimulator cells
Autologous Epstein–Barr virus (EBV)-transformed lympho-
blastoid cell line (B-EBV cells) and autologous blasts were 
generated from the PBMC of each participant isolated before 
challenge. B-EBV cells were obtained by infection of PBMC 
with EBV particles [supernatant from the B95-8 cell line 
(ATCC CRL1612)] and cyclosporine (0.5  μg/ml; Sigma-
Aldrich, Saint-Louis, MO, USA) for 15–30  days. Autologous 
blasts were prepared by 24 h incubating PBMC with 1 μg/ml 
PHA (Sigma-Aldrich, St. Louis, MO, USA) in cRPMI, followed 
by culture in cRPMI supplemented with 20 IU/ml recombinant 
human IL-2 (rhIL-2; Roche, Indianapolis, IN, USA) for 7 days. 
The B cell line 721.222.AEH, which is defective for HLA classi-
cal class I molecules but expresses non-classical class-I HLA-E 
molecules, was provided by Dr. D. Geraghty (20, 22) and cul-
tured in cRPMI supplemented with 200 mU/ml hygromycin B 
(Sigma-Aldrich).
S. Typhi infection of stimulator cells
B-EBV cells, blasts, and AEH cells were incubated for 3 h at 37°C 
with wt S. Typhi strain ISP1820 (at a 7:1 bacteria:target ratio) 
in RPMI free of antibiotics. Cells were washed extensively with 
cRMPI and cultured overnight in cRPMI in the presence of 
gentamicin (150 μg/ml). Infection with S. Typhi was confirmed 
by flow cytometry after staining with anti-Salmonella common 
structural Ag (Kierkegaard & Perry, Gaithersburg, MD, USA) as 
previously described (12).
Ex Vivo stimulation of effector cells
Peripheral blood mononuclear cells were thawed and rested 
in cRPMI overnight before stimulation with S. Typhi-infected 
stimulating cells. Uninfected target (stimulator) cells and 
Staphylococcus enterotoxin B (SEB; 10  μg/ml) were used, 
respectively, as negative and positive controls. Stimulating cells 
were γ-irradiated (6,000 rad) and incubated with PBMC (effector: 
stimulator ratio 5:1) for 2 h in the presence of anti-CD107a (FITC, 
BD Biosciences) monoclonal antibody (mAb) before overnight 
incubation with the protein transport blockers monensin (1 μg/
ml, Sigma) and brefeldin A (2 μg/ml; Sigma).
immunostaining with 14-color Panel mab 
and Flow cytometry analysis
After co-culture with stimulator cells, PBMC were harvested, 
washed in 1× PBS, stained extracellularly, permeabilized, and 
stained intracellularly, using a 14-color panel containing Yellow 
Live/Dead viability kit (Invitrogen, Carlsbad, CA, USA) and 
mAb to CD14-BV570 (M5E2, Biolegend), CD19-BV570 (HIB19, 
Biolegend), CD3-BV650 (OKT3, Biolegend), CD4-PECy5 
(RPA-T4, BD), CD8-PerCP-Cy5.5 (SK1, BD), CD45RA-biotin 
(HI100, BD), CD62L-APC-A780 (DREG-56, Ebioscience), inte-
grin α4β7-A647 (ACT1; conjugated in house) streptavidin(SAV)-
Qdot800 (Invitrogen) CD69-ECD (TP1.55.3, Beckman 
Coulter), IFN-γ-PE-Cy7 (B27, BD), TNF-α-A700 (MAb11, BD), 
IL-2-BV605 (MQ1-17H12, Biolegend), IL-17A-BV421 (BL168, 
Biolegend), and MIP-1β-PE (IC271P, R&D) as previously 
described (11). Samples were acquired using a customized LSRII 
flow cytometer (BD Biosciences) and analyzed using Winlist v7.0 
(Verity Software House, Topsham, ME, USA). Absolute numbers 
of CD3, CD8, CD4 positive cells and CD8 memory subsets cells 
were calculated by using percentages obtained from flow cytom-
etry analysis related to the absolute number of lymphocytes deter-
mined by routine blood count. Responses against S. Typhi were 
expressed as net percentage of positive cells (i.e., total percentage 
of positive cells in the presence of S. Typhi-infected targets minus 
percentage of positive cells in co-cultures with uninfected cells).
statistical analysis
Statistical analyses were performed as previously described 
for participants challenged with a low dose of wt S. Typhi 
(11). Mann–Whitney tests and linear regression analysis were 
performed using Prism v7.02 (GraphPad software, La Jolla, CA, 
USA). Areas under the curve were measured using the trap-
ezoidal method (GraphPad Prism v7.02). p values <0.05 were 
considered significant. Some statistical analyses were based on 
multiple data points from the same individual as indicated in the 
text. For example, in some cases, the same individual provided 
information on cytokine production and/or CD107a expression 
levels after stimulation with three types of stimulations (EBV, 
AEH, and blasts), and these responses we evaluated with regard 
to clinical outcome (i.e., TD vs. NoTD patients). To take advan-
tage of all this information in a single analysis, we used a mixed 
effects model fitted by maximum likelihood. The correlation 
between repeated measures on the same person was accounted 
for by including a random effect per person, using SAS 9.3 (Cary, 
NC, USA).
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resUlTs
Baseline—cD8+ T cell responses against 
S. Typhi correlate with clinical Outcome 
after challenge
The CD8+ T cell compartment is likely to play a major role in 
the CMI response against S. Typhi (7, 13–15, 18). Therefore, 
we first explored whether CD8+ T cell responses at baseline in 
healthy participants challenged with wt S. Typhi could predict 
subsequent typhoid diagnosis. PBMC were obtained from the 
20 participants challenged with the high dose of wt S. Typhi 
(~104 CFU), of whom 13 developed typhoid fever (TD group) 
and 7 did not (NoTD group). PBMC isolated before chal-
lenge (day 0) were stimulated in  vitro with S. Typhi-infected 
autologous B-EBV, S. Typhi-infected autologous blasts, or S. 
Typhi-infected HLA-E-restricted AEH cells. Uninfected cells 
and SEB were used as negative and positive controls, respectively. 
PBMC were surface and intracellularly stained as described in 
Section “Materials and Methods.” Samples were analyzed by 
multichromatic flow cytometry, and CD8+ T cells were selected 
after a gating strategy involving the exclusion of dead cells and 
CD3-CD14+ CD19+ cells. Based on their expression of CD62L 
and CD45RA, CD8+ T cells were subsequently divided into 
naïve T (CD62L+ CD45RA+), T central memory (TCM; CD62L+ 
CD45RA−), T effector memory (TEM; CD62L−CD45RA−), and 
TEM CD45RA+ (TEMRA; CD62L−CD45RA+). No differences 
were observed at baseline between the participants from the 
TD and NoTD groups in the absolute number of white cells, 
lymphocytes, CD3+, CD8+, CD4+, and CD8+ memory subsets 
(Figure S1A in Supplementary Material). Responses against 
S. Typhi were further characterized by co-expression of the T 
cell activation marker CD69 and the cytotoxicity degranulation 
marker CD107a, or the production of IFN-γ, TNF-α, MIP-1β, 
IL-17A, and/or IL-2. Most participants diagnosed with typhoid 
disease (TD) showed higher levels of S. Typhi-responsive T cells at 
baseline than participants who did not develop infection (NoTD) 
(Figure 1). Since these differences were observed after stimula-
tion with each of three different S. Typhi-infected cells (Figure 
S1B in Supplementary Material), we therefore combined results 
from all stimulations for the analyses shown in Figure 1, as well 
as in some subsequent analyses as indicated below. Consistent 
with our previous findings (11), the TEM subset represented the 
major source of intracellular chemokine/cytokine production 
and exhibited the highest expression of CD107a, followed by 
TEMRA and TCM. Interestingly, in TD participants, CD8+ TEM pro-
duced significantly higher levels of IFN-γ, TNF-α, and MIP-1β in 
response to S. Typhi stimulation than in NoTD participants. We 
also observed evidence of an association, albeit not reaching sta-
tistical significance, between development of typhoid disease and 
higher expression of CD107a and production of IL-17A and IL-2 
in CD8+ TEM. Expression of CD107a and cytokine production 
in response to stimulation with S. Typhi-infected cells was also 
significantly higher (TNF-α, MIP-1β), or exhibited a strong trend 
(i.e., they did not reach statistical significance), in CD8+ TEMRA 
and TCM in the participants who developed disease. Interestingly, 
we did not observe statistically significant differences in baseline 
S. Typhi-responses between volunteers who developed typhoid 
disease defined by fever and positive bacterial cultures, and 
those who developed either fever or exhibited a positive bacterial 
culture.
After identifying that the level of baseline responses directed 
against S. Typhi was associated with clinical outcome upon chal-
lenge, we investigated whether there was a relationship between 
these baseline levels and the time to disease diagnosis in TD 
participants. Interestingly, we found a positive trend between 
high baseline levels of all markers and delay in time of disease 
onset (Figure  2). Stronger correlations were observed in the 
TEMRA subset after stimulation with S. Typhi-infected AEH cells, 
where the production of IFN-γ, TNF-α, and MIP-1β before 
challenge and the time to diagnosis were significantly correlated 
(Figure 2). These data indicate that the presence of higher levels 
of S. Typhi-responsive T cells before challenge among the partici-
pants who develop typhoid fever was associated with a delayed 
onset of typhoid fever, suggesting that these T cells could delay, 
but ultimately could not prevent, development of disease.
Distinct clinical Outcomes are 
accompanied by Discrete responses 
against S. Typhi after challenge
After identifying that differences in baseline responses were cor-
related with clinical outcome, we studied the kinetics of immune 
responses until day 28 after challenge. PBMC were obtained from 
12 randomly selected participants, 6 of whom developed typhoid 
fever (TD group) and 6 who did not (NoTD group). Consistent 
with the decreased lymphocyte counts previously reported for the 
TD participants (8), we observed a drop of the absolute numbers 
of CD3+, CD8+, CD4+ T cells before diagnosis (Figure S2A in 
Supplementary Material). We next investigated whether challenge 
with wt S. Typhi elicited multiphasic responses such as those 
observed after vaccination with Ty21a (21, 22). Because of the 
variable responsiveness at baseline in the different participants, the 
net values (day × post-challenge − day 0) were used to normalize 
the data. After challenge, five out of six TD participants showed 
a pronounced decrease in expression of CD107a and production 
of IFN-γ, TNF-α, and MIP-1β in all TM subsets following stimula-
tion with S. Typhi-infected AEH cells, while only minor changes 
were observed in IL-2 and IL-17A production (Figure 3A; Figure 
S3A in Supplementary Material). While only a small decrease was 
observed in the absolute numbers of CD8+ TEM, the decrease was 
striking in absolute numbers of S. Typhi-responsive TEM express-
ing CD107a or producing IFN-γ (Figures S2A,B in Supplementary 
Material). This early drop was followed by a sharp rebound above 
baseline levels after disease onset. In contrast, responses for all 
biomarkers were negligible in five out of the six NoTD par-
ticipants (Figure S3A in Supplementary Material). These distinct 
kinetic patterns were observed consistently after stimulation with 
all the S. Typhi-infected cell types (AEH cells, B-EBV cells, or 
blasts) (Figures 3A–C). However, despite the general similarity 
of the kinetic patterns observed in the TD group, variability in 
the magnitude of the decrease after challenge was noticed among 
participants (Figure S3A in Supplementary Material). To account 
for this variability, we measured the area under the curve below 
FigUre 1 | cD8+ T cell responses against Salmonella enterica serovar Typhi (S. Typhi) at baseline predict the clinical outcome after challenge. 
PBMC isolated at baseline from each participant (TD n = 13, blue; NoTD n = 7, red) were stimulated for 18 h with S. Typhi-infected AEH cells (squares), S. 
Typhi-infected B-EBV cells (circles), or S. Typhi-infected blasts (triangles). After co-culture, cells were immunostained with a 14-color panel of mAbs and analyzed by 
follow cytometry as described in Section “Materials and Methods.” Each symbol represents the net percentage of positive cells measured for CD107a, IFN-γ, 
TNF-α, MIP-1β, interleukin (IL)-17A, and IL-2 in the CD8+ TEM, T effector memory CD45RA+ (TEMRA), and T central memory (TCM) subsets as indicated. Statistical 
analyses were performed using mixed effects models to account for multiple observations per person. *p < 0.05; **p < 0.01.
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FigUre 2 | high levels of cD8+ T cell responses against Salmonella enterica serovar Typhi (S. Typhi) are associated with delayed time to diagnosis. 
After stimulation of PBMC with S. Typhi-infected AEH cells, percentages of CD107a, IFN-γ, TNF-α, MIP-1β, interleukin (IL)-17A, and IL-2-positive cells in the CD8+ 
TEM and T effector memory CD45RA+ (TEMRA) subsets were plotted against time to diagnosis for each participant who developed typhoid fever (n = 13). Correlations 
(red lines) were assessed using the linear regression function and Pearson’s tests of GraphPad Prism v7.02. *p < 0.05.
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baseline for all early time points, and investigated whether the 
magnitude of the decrease in response to S. Typhi-infected cells 
was related to the baseline levels. A positive trend was noted for 
all functions in each of the TM subsets, and significant correla-
tions were observed for CD107a, IFN-γ, TNF-α, and IL-2 in TEM 
cells (Figure 3D). Of note, TEM cells showed a more pronounced 
decrease for most functions, followed by TEMRA and TCM cells 
(Figure S3B in Supplementary Material).
enhanced gut homing Potential of S. 
Typhi-responsive cD8+ T cells in 
Participants Diagnosed with Typhoid 
Disease
The mucosal immunity mounted in the gut microenvironment, 
the site of entry for S. Typhi, is a major element in the protection 
against typhoid fever after vaccination with live oral typhoid 
vaccines (16, 19). Therefore, we sought to assess if the selective 
migration of CD8+ T cells to the small intestine, driven by the 
gut homing molecule integrin α4β7, was potentially contributing 
to the decrease in responses against S. Typhi observed soon after 
challenge. PBMC were obtained at baseline from the 20 par-
ticipants (13 TD and 7 NoTD participants), and after challenge 
from the 12 randomly selected participants (6 from TD group 
and 6 from NoTD group). We first measured the expression 
of integrin α4β7 ex vivo, in total CD8+ TEM cells, and found no 
difference in the baseline proportion of integrin α4β7 expressing 
cells between the two groups of participants (Figure  4A). In 
both groups, the percentages of integrin α4β7+ CD8+ TEM cells 
represented approximately one third of the total CD8+ TEM cells. 
Interestingly, a decline in the proportion of integrin α4β7+ CD8+ 
TEM was observed around the time of diagnosis (d6–d9) for TD 
participants, while this proportion remained unchanged for 
NoTD participants (Figures 4B,C).
FigUre 3 | Distinct kinetics of responsive cD8+ T cell responses against Salmonella enterica serovar Typhi (S. Typhi) after challenge. (a) Kinetics for 
a representative participant from each group (TD and NoTD) showing the production of cytokines/chemokines and expression of CD107a by CD8+ TEM following 
stimulation with S. Typhi-infected AEH cells at different time points after challenge. (B,c) Kinetics of IFN-γ production is shown for a representative volunteer after 
stimulation with S. Typhi-infected B-EBV cells and S. Typhi-infected blasts. (D) Areas under the curve below baseline were measured until time to diagnosis for the 
six randomly selected TD participants and plotted against the baseline level of responses for each of the indicated biomarkers stimulated with S. Typhi-infected AEH 
cells (squares), S. Typhi-infected B-EBV cells (circles), or S. Typhi-infected blasts (triangles). Correlations analyses were performed using mixed effects models to 
account for multiple observations per person. **p < 0.01.
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We next measured the expression of integrin α4β7 on S. Typhi-
responsive activated (CD69+) TM subsets after stimulation with 
S. Typhi-infected cells (AEH cells, B-EBV cells, or blasts). We 
observed no differences in the percentages of integrin α4β7− and 
integrin α4β7+ activated TEM cells between the two groups of 
participants at baseline (Figure  5A). Early after challenge, TD 
participants showed similar decreases in both integrin α4β7− and 
integrin α4β7+ S. Typhi-responsive TEM, and both populations 
rebounded over baseline after disease diagnosis (Figure 5B). No 
changes were observed in NoTD participants.
S. Typhi-responsive cD8+ TM cells are 
Primarily MF
We and others have recently described that concomitant produc-
tion of cytokines/chemokines and/or expression of CD107a at 
the single cell level (MF cells) are likely to be a critical factor 
FigUre 4 | gut homing potential of total cD8+ TeM. (a) Each value represents the baseline percentages of integrin α4β7− and integrin α4β7+ cells in total CD8+ 
TEM evaluated by surface staining and flow cytometry for 12 randomly selected TD (squares) and NoTD (circles) participants. *p < 0.05. (B) Ratio of integrin α4β7+ to 
integrin α4β7− total CD8+ TEM cells are shown within four periods of time after challenge. Period d6–d9 corresponds to the time of typhoid diagnosis. Statistical 
analyses were performed using mixed effects models to account for multiple observations per person. **p < 0.01. (c) Kinetics of expression of integrin α4β7+ total 
CD8+ TEM after challenge in representative participants from each group.
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in shaping the quality of protective immune responses (11, 21, 
22, 25, 26). Therefore, we closely examined the proportion and 
characteristics of all possible combinations of the six functional 
biomarkers (i.e., a total of 64 possible combinations) measured 
in CD8+ TEM cells. PBMC were obtained at baseline from the 
20 participants (13 TD and 7 NoTD), and after challenge from 
12 randomly selected participants (6 TD and 6 NoTD). For ease 
analysis, we first grouped them into single positive (1+) or MF 
cells, i.e., cells positive for two or more biomarkers (Figure 6A). 
At baseline, the MF populations were significantly higher in par-
ticipants diagnosed with typhoid disease (Figure 6A). This was 
also observed in the numbers of absolute numbers of single and 
MF cells (Figure S4A in Supplementary Material). In addition, 
to explore the gut homing potential of these S. Typhi-responsive 
MF T cells, we measured their expression of integrin α4β7. We 
observed that the proportions of MF were similar in both integrin 
α4β7− and integrin α4β7+ TEM (Figure 6A). To further characterize 
the MF responses, we categorized them into double (2+), triple 
(3+), quadruple (4+), and quintuple-sextuple (5–6+) positive 
subsets, based on the number of biomarkers they exhibited. We 
observed that double, triple, and quadruple positive populations 
comprise the dominant populations of MF CD8+ TEM in TD and 
NoTD participants (Figure  6B). However, these populations 
were significantly higher in the participants who developed dis-
ease. Of note, these MF cells were equally represented by integrin 
α4β7− and integrin α4β7+ expressing TEM subsets. We further 
focused on the precise characteristics of the individual MF popu-
lations and identified the nine dominant (i.e., highest frequency) 
MF patterns among all possible combinations (Figure  6C). 
Together, these nine populations represented 65–85% of the total 
S. Typhi-responsive MF cells. Interestingly, eight out of the nine 
distinct populations were significantly higher in participants 
who were diagnosed with typhoid disease. The production of the 
chemokine MIP-1β was a common feature as it was produced by 
eight out of the nine MF populations. CD107a, IFN-γ, and TNF-α 
were also present in six out of nine populations, while IL-2 was 
detected at much lower frequencies. The CD107a+IFN-γ+TNF-
α+MIP-1β+ population was predominant, followed by four 
subdominant populations defined as CD107a+TNF-α+MIP-
1β+, CD107a+IFN-γ+MIP-1β+, IFN-γ+TNF-α+MIP-1β+, and 
CD107a+IFN-γ+TNF-α+MIP-1β+IL-2+. IL-17A was detected 
at lower levels and was not produced by any of the nine dominant 
populations. The nine dominant populations were also equally 
represented in integrin α4β7− and integrin α4β7+ expressing TEM 
subsets (Figure S4B in Supplementary Material).
Finally, we investigated post-challenge responses directed 
against S. Typhi at 48 h after typhoid diagnosis or day 7 post chal-
lenge in TD and NoTD participants, respectively, and found that, 
similar to baseline, MF responses were dominant (Figure 7A). 
Double, triple, and quadruple positive populations were the 
FigUre 5 | gut homing potential of Salmonella enterica serovar Typhi (S. Typhi)-responsive memory cD8+ T cell subsets. (a) Each value represents the 
percentage of integrin α4β7+ cells in S. Typhi-responsive CD8+ TEM, T effector memory CD45RA+ (TEMRA), and T central memory (TCM) cell subsets at baseline for 
each participant (TD n = 13, NoTD n = 7) following stimulation with S. Typhi-infected cells [AEH cells (squares), B-EBV (circles), or blasts (triangles)]. (B) Kinetics of 
the percentages of integrin α4β7− and integrin α4β7+ S. Typhi-responsive CD8+ TEM are shown for a representative participant in each group. Statistical analyses 
were performed using mixed effects models to account for multiple observations per person.
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dominant MF cells (Figure 7B). Significant decreases in the per-
centages of only two of the nine dominant MF populations, i.e., 
CD107a+IFN-γ+TNF-α+MIP-1β+ and IFN-γ+TNF-α+MIP-
1β+, occurred 48 h after typhoid diagnosis compared to baseline 
(Figure  7C). The dominance of MF populations was similar 
in both integrin α4β7− and integrin α4β7+ S. Typhi-responsive 
TEM subsets (Figures S5A–C in Supplementary Material). Taken 
together, these results highlight a strong MF component of CD8+ 
TEM responses, both at baseline and after challenge.
DiscUssiOn
The investigation of immune responses in typhoid fever, particu-
larly CMI, has been largely restricted to studies in endemic areas 
or following vaccination. Very limited data are available on the 
S. Typhi-specific immune status prior to infection with wt S. Typhi 
or on the immune correlate(s) of protection. This challenge study 
allowed us to investigate relationships between baseline levels 
of responses directed against S. Typhi and the development of 
typhoid disease. We have very recently published a description of 
the CMI responses for the cohort of participants challenged with 
a low dose (~103 CFU) of wt S. Typhi (11). Herein, we report the 
results of CMI studies in participants challenged with a high dose 
of wt S. Typhi (~104 CFU) that show higher baseline responses 
against S. Typhi to be associated with typhoid fever diagnosis. 
After challenge, TD participants showed decreases in both the 
percentages of S. Typhi-responsive CD8+ cells and absolute 
numbers of CD3+, CD8+, and CD4+ T cells, an observation con-
sistent with the reported drop of lymphocyte counts described 
before diagnosis in TD participants (8) and with our previous 
FigUre 6 | continued
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FigUre 7 | characterization of multifunctional (MF) cD8+ TeM responses against Salmonella enterica serovar Typhi (S. Typhi) after challenge. Flow 
cytometry data were analyzed as described in Figure 6. Percentages were measured at day 7 for six NoTD participants and at 48 h after typhoid diagnosis for six 
TD participants. (a) Percentages of single positive cells (1+) or of total MF cells. (B) Total MF cells were divided into four groups on the basis of the number of 
biomarkers they expressed. (c) The nine major individual populations of MF in TD participants are represented at baseline (orange) or 48 h after TD diagnosis  
(dark green).
FigUre 6 | continued 
characterization of multifunctional (MF) cD8+ TeM responses against Salmonella enterica serovar Typhi (S. Typhi) at baseline. Flow cytometry data 
were analyzed using the FCOM function of Winlist to determine the proportion of all possible combinations of the six measured biomarkers to identify MF cells (i.e., 
positive for several biomarkers concomitantly). Each symbol represents the percentage of the different populations measured after stimulation with S. Typhi-infected 
cells [AEH cells (squares), B-EBV (circles) cells, or blasts (triangles)] for each participant (TD n = 13, NoTD n = 7). (a) The percentages of single positive cells (1+) or 
of total MF cells (i.e., the sum of all cells concomitantly positive for two or more biomarkers) are represented for all CD8+ TEM and for CD8+ TEM integrin α4β7− and 
integrin α4β7+ cells. (B) MF cells were divided into four groups on the basis of the number of biomarkers they expressed [e.g., cells expressing two biomarkers are 
shown as double positive (2+)]. (c) Characterization of the nine major individual populations of S. Typhi-responsive MF in CD8+ TEM. *p < 0.05, **p < 0.01, 
***p < 0.001.
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findings in the group of participants challenged with the lower 
dose of S. Typhi (11).
Selective homing to the gut, the site of entry for S. Typhi, 
is driven to a large extent by the expression of the gut homing 
molecule integrin α4β7 (18, 27–30). In the present study, TD 
participants show decreases in both S. Typhi-responsive integrin 
α4β7− and integrin α4β7+ CD8+ TEM cells after challenge, sug-
gesting that migration of the CD8+ TEM might be associated with 
the development of typhoid fever and that S. Typhi-responsive 
TEM cells migrate not only to mucosal sites but also to other 
sites, presumably other RES components (e.g., peripheral lymph 
nodes, spleen). Their presence in secondary lymphoid tissues may 
restrict replication of S. Typhi during the incubation phase, delay-
ing the onset of disease. These results are similar to those that we 
recently reported in the group of Oxford participants challenged 
with the lower dose of S. Typhi (11) and are in agreement with our 
previous observations after vaccination (16, 18, 19).
Interestingly, studies of acute S. Typhimurium infection in 
mouse models have shown that pathogenic bacteria can exploit 
inflammation in order to overcome the protective microbiota 
(31, 32). In contrast to the findings, we reported in the cohort 
of TD participants challenged with the lower dose of S. Typhi 
(11), among TD participants who received a higher inoculum 
those with higher baseline responses against S. Typhi were more 
likely to acquire disease. The contrasting association of clinical 
outcome and levels of S. Typhi-responsive CD8+ responses 
observed between the two groups of participants (i.e., those 
challenged with 103 vs. 104 CFU of wt S. Typhi) could be related 
to the presence of a larger number of wt S. Typhi organisms in 
the gastrointestinal mucosa in the group receiving 104 CFU of 
wt S. Typhi. Although the data currently available do not allow 
us to fully explain these observations, it is reasonable to specu-
late that this larger numbers of S. Typhi organisms triggered a 
stronger inflammatory response than that induced with the lower 
inoculum and that this increased inflammation could favor the 
systemic spread of S. Typhi, ultimately leading to the develop-
ment of typhoid fever. Moreover, the migration of large numbers 
of S. Typhi-responsive CD8+ T cells to the sites of infection 
might also play a role in the inflammatory responses. Additional 
information will be provided by ongoing studies directed to 
extend the current observations, which are based on a relatively 
small number of volunteers. These studies involve volunteers 
who participated in a follow-up clinical trial in which they were 
immunized, or not, with S. Typhi vaccines and then challenged 
with a high dose of wt S. Typhi.
Of great importance, we also show that higher classical and 
non-classical (HLA-E) class I MHC-restricted S. Typhi-specific 
baseline responses against S. Typhi among TD participants were 
associated with a delayed time to diagnosis, suggesting that S. 
Typhi-responsive CD8+ responses play a role in protection. 
These decreases in circulating S. Typhi-responsive T cells after 
challenge are proportional to the levels present at baseline, sug-
gesting that the higher the pool of S. Typhi-responsive T cells 
available in circulation at baseline, the higher the number of 
these cells that are recruited to the site of pathogen encounter. 
Similar observations were reported in the group of participants 
challenged with the lower dose of wt S. Typhi (11). Based on 
these observations, we hypothesize that in TD participants the 
numbers of S. Typhi-responsive T cells recruited to the gut are 
sufficient to reach the threshold of inflammation necessary for S. 
Typhi to spread, but only participants with the highest numbers 
of S. Typhi-responsive T cells were able to initially delay S. Typhi 
dissemination, likely by decreasing the number of infectious 
organisms. Alternatively, or in addition, it is likely that the 
balance between suppressive and pro-inflammatory responses 
might also be important in the host’s ability to mount effective 
immune responses.
Exposure to wt S. Typhi might elicit S. Typhi-responsive 
regulatory T cells (Treg), which could suppress S. Typhi-responsive 
TEM responses and contribute to the development of typhoid 
disease. This hypothesis is supported by studies in the murine 
S. Typhimurium model showing that the balance of suppressive 
Treg and pro-inflammatory T cell responses influence bacterial 
clearance or persistence (33). We have recently described an 
upregulation of the gut homing molecule integrin α4β7 on S. 
Typhi-responsive Treg in TD participants pre-challenge, followed 
by a significant downregulation post-challenge (34), suggesting 
possible Treg homing to the gut. Additionally, S. Typhi-responsive 
Treg from TD participants exhibited an upregulation of activation 
molecules post-challenge and in vitro depletion of Treg resulted 
in increased cytokine production by CD8+ TEM. These results 
suggest that activated Treg may play a pivotal role in typhoid fever, 
possibly through suppression of S. Typhi-responsive effector T 
cell responses (34). It is unclear whether similar Treg responses 
were also elicited in the participants challenged with the low dose 
of wt S. Typhi and whether they could account, at least in part, 
for the differences observed in T effector baseline responses and 
clinical outcome between participants who received the low and 
high doses of wt S. Typhi.
It is also possible that other functional characteristics of S. 
Typhi-specific cells at baseline are important in defining the 
clinical outcome following challenge. Among these, the levels of 
exhausted S. Typhi-specific cells at baseline could be an impor-
tant determinant. Exhausted T cells express the programmed 
death-1 receptor and are characterized by poor effector function 
that prevents optimal control of infections (35, 36). In our MF 
analysis, we noted that IFN-γ and TNF-α [typically expressed by 
PD1+ cells (37)] and which are potent inducers of PD-Ligand1 
(38) were co-expressed in the dominant MF populations of S. 
Typhi-responsive T cells. Ongoing studies directed to assess the 
levels and functional properties of PD-1+ S. Typhi-specific cells 
in participants vaccinated with Ty21a, or not, and subsequently 
challenged with wt S. Typhi will help establish the validity of 
this hypothesis. In addressing the immunological differences 
observed between low and high doses of wt S. Typhi and their 
association with clinical outcome, we should also consider that 
in this stringent high-dose controlled human infection study, 
participants were exposed to high doses of pathogen, which are 
likely to exceed the number of infectious S. Typhi organisms 
expected to be ingested in the natural environment and which 
could have overwhelmed the host’s ability to successfully combat 
infection.
Numerous studies suggest that S. Typhi has the ability to 
reduce intestinal inflammation by several mechanisms including 
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regulation of the innate immune signaling pathways (39), escape 
from recognition by innate immune cells (40), inhibition of anti-
gen presentation by dendritic cells (41), or direct inhibition of T 
cells (42, 43). The possibility that S. Typhi might escape immune 
recognition and that this might play a key role in limiting inflam-
matory responses is supported by the fact that a few participants 
in this study were bacteremic without any reported symptoms. 
Similar observations were previously described in the Maryland 
challenges (5).
In this study, we provide additional information that the 
CD8+ TEM subset is the major effector in responses against S. 
Typhi and show that these responses are mostly MF. These 
observations extend previous studies in humans and non-human 
primates demonstrating that the quality of the MF response is 
likely to play a critical role in immune responses against S. 
Typhi (25, 26, 44–46). Production of MIP-1β is a leading feature 
of S. Typhi-responsive MF populations, including the most 
dominant MF subset, i.e., CD107a+IFN-γ+TNF-α+MIP-1β+ 
cells. MIP-1β exerts a crucial role in tilting immune responses 
toward inflammation (47). In addition, MIP-1β has also been 
shown to be involved in CTL activity and its expression by HIV 
antigen-responsive CD8+ T cells in non-progressors suggests 
that it might play a role in controlling infection (46). In S. Typhi 
infections we previously described the co-production of MIP-
1β with IFN-γ, TNF-α, IL-17A, and IL-2, as well as expression 
of CD107a following vaccination with Ty21a (22, 48). MIP-1β 
was also reported to be produced by PBMC obtained from S. 
Typhi-infected convalescent patients (49). Taken together, these 
observations suggest that coproduction of MIP-1β with other 
cytokines is a key component of responses against S. Typhi-and 
that, depending on the characteristics of the response (e.g., 
production of other cytokines/chemokines, kinetics, magnitude, 
microenvironment, other unknown factors), it may either play 
a key role in protection or in the development of inflammation 
leading to typhoid disease.
We observed that protection against typhoid fever is associ-
ated with very low or no baseline responses against S. Typhi and 
no changes in circulating S. Typhi-responsive TM after challenge. 
These kinetic patterns were also consistently observed in the NoTD 
participants challenged with a lower dose (11). It is reasonable to 
hypothesize that in NoTD participants S. Typhi was controlled by 
innate and/or adaptive immune responses in the mucosa of the 
gastrointestinal tract, precluding S. Typhi from becoming invasive 
and causing disease. Although the mechanisms underlying the 
control of S. Typhi infection remain unclear, mucosal-associated 
invariant T (MAIT) cells may be one of the cell types involved. 
MAIT cells are a CD8+ cell subset expressing CD161 and TCR 
Vα7.2 and restricted by the MR1 MHC-related molecule, which 
has been postulated to play an important role in mucosal immu-
nity (50). Our recent observations show that MAIT cells isolated 
from healthy individuals not previously exposed to S. Typhi 
are able to produce IL-17A, IFN-γ, and TNF-α when exposed 
to S. Typhi-infected cells (51). Conventional antigen-responsive 
T cells such as tissue-resident memory T cells, TCRγ/δ T cells, 
and NK-T cells may also help to provide protection in the gut 
microenvironment (52). Measurements of MAIT cell responses, 
as well as those of other subsets, in the challenged participants 
before and after exposure to wt S. Typhi will help clarify their role 
in typhoid fever.
In contrast to our observations on CD8+ baseline responses, 
higher baseline titers of antibodies directed against S. Typhi 
were not associated with development of disease (8). However, 
increases in S. Typhi-specific LPS and H antibodies post-challenge 
were associated with typhoid fever, while little change was seen in 
participants who did not develop disease. Further studies will be 
required to fully characterize the role of anti-S. Typhi antibodies 
in typhoid fever.
Since very few data are available on the baseline immune 
responses in the context of typhoid fever, the reasons for the dis-
parity observed between baseline responses against S. Typhi and 
clinical outcome between the low and high dose participants are 
unclear. Participants were recruited in the UK, a non-endemic 
region (i.e., it is very unlikely that they have previously encoun-
tered S. Typhi), and they have not been vaccinated against 
typhoid; therefore, they were considered “naïve.” However, 
the S. Typhi genome has approximately 90% homology with 
other Salmonella serovars (53), and immune cross-reactivity 
has been described with S. Paratyphi A and B as well as vari-
ous non-typhoidal Salmonella (54). Cross-reactive responses 
may also be elicited by exposure to other Enterobacteriaeceae. 
Consequently, differences in baseline responses could be due 
to memory responses mounted from previous encounters with 
other enteric Gram negative bacilli, including those present in 
the normal gut microbiota (7, 55, 56). Several studies indicate 
that the gut microbiota plays an important role in modulating 
host immune responses to pathogens or to vaccination (55–57). 
For example, we have recently reported in healthy adults that 
oral administration of the Ty21a live-attenuated S. Typhi vac-
cine caused no disruption in the composition, diversity, or 
stability of the fecal microbiota. However, we observed that 
distinct multiphasic CMI responses were associated with greater 
community richness and diversity compared to individuals 
with only late CMI responses to Ty21a (56). To assess the role 
of the gut microbial community, we have initiated studies to 
identify the interplay between the host immune response, the 
microbiota and clinical outcome in participants challenged with 
wt S. Typhi.
In addition to these environmental factors, genetic deter-
minants, like HLA molecules, can be critical in defining the 
variation in immune responses. For example, the presence of 
the HLA-DRB1*04:05 allele was recently shown to be strongly 
protective against S. Typhi (58).
In summary, these studies provided unique insights into the 
vast complexity of the human host immune response during 
the development of typhoid fever. Baseline responses of S. 
Typhi-responsive CD8+ T cells were identified as significant 
correlates of clinical outcome after infection. These studies also 
revealed some of the immunological mechanisms responsible 
for delayed time to disease onset and demonstrated that MF 
T cells are likely to play a key role in the host’s response to 
wt S. Typhi infection. Finally, this information reinforces the 
importance of conducting detailed CMI measurements to sup-
port the selection of future vaccine candidates for evaluation 
in clinical trials.
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